MNTA: If Copaxone has been fully characterized, it is a reasonable assumption that Lovenox was fully characterized. Any clues on whether MNTA/Sandoz would launch "at-risk" if FDA approves mCopaxone?
"If we don't succeed, we run the risk of failure." -Dan Quayle